Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Luvometinib in Combination With Serplulimab for NF2-Related Tumors

14. juli 2026 oppdatert av: Beijing Tiantan Hospital

A Multicenter, Open-Label Study of Luvometinib in Combination With Serplulimab for the Treatment of NF2-Related Tumors

This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.

Studieoversikt

Detaljert beskrivelse

NF2-related schwannomatosis (NF2-SWN) is a rare autosomal dominant disorder characterized by multiple central nervous system tumors, most commonly vestibular schwannomas and meningiomas. Although current treatments such as surgery and radiotherapy can provide disease control, they are not curative and are associated with cumulative neurological morbidity and potential risk of secondary malignancies. There remains a significant unmet need for effective systemic therapies.

This investigator-initiated study is conducted as a substudy within the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The trial evaluates luvometinib in combination with serplulimab in patients with progressive NF2-SWN.

Luvometinib (FCN-159) is a selective MEK1/2 inhibitor with antitumor activity in NF1-associated tumors. Serplulimab (HLX10) is an anti-PD-1 monoclonal antibody approved for multiple solid tumors. Preclinical evidence suggests that MEK inhibition may enhance tumor immunogenicity and synergize with immune checkpoint blockade.

The study aims to assess the safety, tolerability, and preliminary efficacy of this combination in NF2-SWN.

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100853
        • Chinese PLA General Hospital
        • Ta kontakt med:
      • Beijing, Beijing Municipality, Kina, 100070
        • Beijing Tiantan Hospital, Capital Medical University
        • Ta kontakt med:
      • Beijing, Beijing Municipality, Kina, 100053
        • Xuanwu Hospital, Capital Medical University
        • Ta kontakt med:
    • Jilin
      • Changchun, Jilin, Kina
        • The First Hospital of Jilin University
        • Ta kontakt med:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200080
        • Shanghai General Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Participants must meet the diagnostic criteria for NF2-SWN.
  2. Presence of at least one measurable target tumor, either vestibular schwannoma or meningioma, with MRI-documented volumetric progression within the past 36 months or clinical symptom progression related to the target tumor.
  3. The target tumor is considered unsuitable for surgery because of high risk.
  4. Age >=18 years at the time of screening.
  5. KPS >=70 or ECOG performance status 0 or 1.
  6. Adequate organ function based on laboratory tests obtained within 14 days before screening.
  7. Participant must be able to understand the study and voluntarily sign informed consent.

Exclusion Criteria:

  1. Pregnant, planning to become pregnant, or currently breastfeeding.
  2. Participation in another interventional clinical trial within the past 4 weeks, or radiation therapy to target lesion(s) within the past 3 years.
  3. Severe adverse reactions or intolerable toxicity from prior immune checkpoint inhibitors or MEK inhibitors.
  4. Concomitant active malignancies, uncontrolled infections, or active autoimmune diseases.
  5. Severe cardiac, hepatic, renal, gastrointestinal, or ophthalmic diseases.
  6. Any other factor that may compromise participant safety or study integrity.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Luvometinib + Serplulimab
Subjects will receive luvometinib 8 mg by mouth once daily in combination with serplulimab 4.5 mg/kg intravenously every 3 weeks for up to 12 cycles (28 days per cycle).
Oral once daily per predetermined dosage per protocol.
Andre navn:
  • FCN-159
Intravenous infusion per predetermined dosage per protocol.
Andre navn:
  • HLX10

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR) or Hearing Response Rate (HRR)
Tidsramme: 12 months

Vestibular schwannoma: HRR is defined as WRS improvement exceeding the 95% critical difference from baseline; if baseline WRS is <20%, HRR is defined as a PTA decrease of at least 10 dB.

Meningioma: ORR is defined as at least a 20% reduction in target tumor volume from baseline.

12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Adverse Events
Tidsramme: From first dose through 30 days after last dose (up to 12 months)
Percentage of participants who experience at least one adverse event. Adverse events will be coded and graded according to NCI CTCAE v5.0.
From first dose through 30 days after last dose (up to 12 months)
Maximum Severity Grade of Adverse Events
Tidsramme: From first dose through 30 days after last dose (up to 12 months)
Maximum NCI CTCAE v5.0 grade of adverse events experienced by each participant during the reporting period.
From first dose through 30 days after last dose (up to 12 months)
Incidence of Serious Adverse Events
Tidsramme: From first dose through 30 days after last dose (up to 12 months)
Percentage of participants who experience at least one serious adverse event.
From first dose through 30 days after last dose (up to 12 months)
Incidence of Dose Modifications
Tidsramme: From first dose through 30 days after last dose (up to 12 months)
Percentage of participants who require at least one dose modification due to an adverse event.
From first dose through 30 days after last dose (up to 12 months)
Incidence of Treatment Interruptions
Tidsramme: From first dose through 30 days after last dose.
Percentage of participants who require at least one treatment interruption due to an adverse event.
From first dose through 30 days after last dose.
Incidence of Treatment Discontinuations
Tidsramme: From first dose through 30 days after last dose.
Percentage of participants who discontinue study treatment due to an adverse event.
From first dose through 30 days after last dose.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

31. juli 2026

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. desember 2029

Datoer for studieregistrering

Først innsendt

3. juli 2026

Først innsendt som oppfylte QC-kriteriene

14. juli 2026

Først lagt ut (Faktiske)

16. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. juli 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere